The initial agreement period is for three years, and is subject to annual minimum guaranteed orders of CytoSorb in order to maintain exclusivity.
Hitit Medical managing director Tankut Gedik noted that as a company with extensive expertise in extracorporeal therapy, Hitit has followed the progress of CytoSorb since its launch in the European Union last year.
"We are very excited to be the exclusive distributor of such an advanced technology in the Turkish market. We were attracted by CytoSorb’s proven ability to safely reduce cytokine storm in critically ill patients, its potential to prevent or treat organ failure, and its ease of use across many different hemodialysis machine platforms. We have now registered CytoSorb® in Turkey, and have had a strong response from physicians eager to evaluate this powerful new therapy," Gedik added.
CytoSorbents chief operating officer Vincent Capponi said that the company is excited to bring Hitit Medical on board as part of a global expansion program to drive usage of CytoSorb beyond the European Union.
"Turkey, with its modern medical facilities and infrastructure in accredited hospitals and common use of blood purification technologies, is an ideal first country to target outside the EU," Capponi added.
